Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases

1.

Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017;19(2):162–74.

CAS  Article  Google Scholar 

2.

Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res. 2010;16(23):5664–78.

CAS  Article  Google Scholar 

3.

Boire A, Brastianos PK, Garzia L, Valiente M. Brain metastasis. Nat Rev Cancer. 2020;20(1):4–11.

CAS  Article  Google Scholar 

4.

Gaspar LE, Chansky K, Albain KS, Vallieres E, Rusch V, Crowley JJ, et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol. 2005;23(13):2955–61.

Article  Google Scholar 

5.

Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19(11):1511–21.

Article  Google Scholar 

6.

Sun A, Bae K, Gore EM, Movsas B, Wong SJ, Meyers CA, et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol. 2011;29(3):279–86.

Article  Google Scholar 

7.

Sun A, Hu C, Wong SJ, Gore E, Videtic G, Dutta S, et al. Prophylactic cranial irradiation vs observation in patients with locally advanced non-small cell lung cancer: a long-term update of the NRG Oncology/RTOG 0214 phase 3 randomized clinical trial. JAMA Oncol. 2019;5(6):847–55.

Article  Google Scholar 

8.

Suh JH, Kotecha R, Chao ST, Ahluwalia MS, Sahgal A, Chang EL. Current approaches to the management of brain metastases. Nat Rev Clin Oncol. 2020;17(5):279–99.

Article  Google Scholar 

9.

NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer Version 3.2020 [Internet]. National Comprehensive Cancer Network (NCCN). 2020.

10.

Aoyama H, Tago M, Shirato H, Japanese Radiation Oncology Study Group I. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99–1 randomized clinical trial. JAMA Oncol. 2015;1(4):457–64.

Article  Google Scholar 

11.

Jiang T, Su C, Li X, Zhao C, Zhou F, Ren S, et al. EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases. J Thorac Oncol. 2016;11(10):1718–28.

Article  Google Scholar 

12.

Doherty MK, Korpanty GJ, Tomasini P, Alizadeh M, Jao K, Labbe C, et al. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer. Radiother Oncol. 2017;123(2):195–202.

Article  Google Scholar 

13.

Singh M, Venugopal C, Tokar T, Brown KR, McFarlane N, Bakhshinyan D, et al. RNAi screen identifies essential regulators of human brain metastasis-initiating cells. Acta Neuropathol. 2017;134(6):923–40.

CAS  Article  Google Scholar 

14.

Singh M, Venugopal C, Tokar T, McFarlane N, Subapanditha MK, Qazi M, et al. Therapeutic targeting of the premetastatic stage in human lung-to-brain metastasis. Cancer Res. 2018;78(17):5124–34.

CAS  Article  Google Scholar 

15.

Singh M, Manoranjan B, Mahendram S, McFarlane N, Venugopal C, Singh SK. Brain metastasis-initiating cells: survival of the fittest. Int J Mol Sci. 2014;15(5):9117–33.

CAS  Article  Google Scholar 

16.

Celia-Terrassa T, Kang Y. Distinctive properties of metastasis-initiating cells. Genes Dev. 2016;30(8):892–908.

CAS  Article  Google Scholar 

17.

Massague J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016;529(7586):298–306.

CAS  Article  Google Scholar 

18.

Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003;3(4):253–66.

CAS  Article  Google Scholar 

19.

Paluszczak J, Baer-Dubowska W. Epigenetic diagnostics of cancer–the application of DNA methylation markers. J Appl Genet. 2006;47(4):365–75.

Article  Google Scholar 

20.

Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol. 2016;8(9).

21.

Hao X, Luo H, Krawczyk M, Wei W, Wang W, Wang J, et al. DNA methylation markers for diagnosis and prognosis of common cancers. Proc Natl Acad Sci U S A. 2017;114(28):7414–9.

CAS  Article  Google Scholar 

22.

Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Consortium C. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745–59.

CAS  Article  Google Scholar 

23.

Nikolaidis G, Raji OY, Markopoulou S, Gosney JR, Bryan J, Warburton C, et al. DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer. Cancer Res. 2012;72(22):5692–701.

CAS  Article  Google Scholar 

24.

Xia S, Ye J, Chen Y, Lizaso A, Huang L, Shi L, et al. Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients. Transl Lung Cancer Res. 2019;8(6):1016–28.

CAS  Article  Google Scholar 

25.

Soes S, Daugaard IL, Sorensen BS, Carus A, Mattheisen M, Alsner J, et al. Hypomethylation and increased expression of the putative oncogene ELMO3 are associated with lung cancer development and metastases formation. Oncoscience. 2014;1(5):367–74.

Article  Google Scholar 

26.

Li YS, Jiang BY, Yang JJ, Zhang XC, Zhang Z, Ye JY, et al. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy. Ann Oncol. 2018;29(4):945–52.

CAS  Article  Google Scholar 

27.

Chen X, Fang L, Zhu Y, Bao Z, Wang Q, Liu R, et al. Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients. Cancer Immunol Immunother. 2021;70(12):3513–24.

CAS  Article  Google Scholar 

28.

Liang N, Li B, Jia Z, Wang C, Wu P, Zheng T, et al. Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning. Nat Biomed Eng. 2021;5(6):586–99.

CAS  Article  Google Scholar 

29.

Liu L, Zhao T, Zhong Q, Cui J, Xiu X, Li G. The role of prophylactic cranial irradiation in patients with non-small cell lung cancer: an updated systematic review and meta-analysis. Front Oncol. 2020;10:11.

CAS  Article  Google Scholar 

30.

Witlox WJA, Ramaekers BLT, Zindler JD, Eekers DBP, van Loon JGM, Hendriks LEL, et al. The prevention of brain metastases in non-small cell lung cancer by prophylactic cranial irradiation. Front Oncol. 2018;8(241):241.

Article  Google Scholar 

31.

Ding X, Dai H, Hui Z, Ji W, Liang J, Lv J, et al. Risk factors of brain metastases in completely resected pathological stage IIIA-N2 non-small cell lung cancer. Radiat Oncol. 2012;7(1):119.

Article  Google Scholar 

32.

Arrieta O, Salas AA, Cardona AF, Diaz-Garcia D, Lara-Mejia L, Escamilla I, et al. Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease. Lung Cancer. 2021;155:183–90.

Article  Google Scholar 

33.

Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455(7216):1069–75.

CAS  Article  Google Scholar 

34.

Matsumoto S, Iwakawa R, Takahashi K, Kohno T, Nakanishi Y, Matsuno Y, et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene. 2007;26(40):5911–8.

CAS  Article  Google Scholar 

35.

Ji M, Liu Y, Li Q, Li XD, Zhao WQ, Zhang H, et al. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. J Transl Med. 2015;13:5.

Article  Google Scholar 

36.

Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature. 2004;431(7008):525–6.

CAS  Article  Google Scholar 

37.

M JD, Wojtas B. Global DNA Methylation patterns in human gliomas and their interplay with other epigenetic modifications. Int J Mol Sci. 2019;20(14).

38.

Antonelli M, Fadda A, Loi E, Moi L, Zavattari C, Sulas P, et al. Integrated DNA methylation analysis identifies topographical and tumoral biomarkers in pilocytic astrocytomas. Oncotarget. 2018;9(17):13807–21.

Article  Google Scholar 

39.

Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015;5(11):1164–77.

CAS  Article  Google Scholar 

40.

Li Y, Liu B, Connolly ID, Kakusa BW, Pan W, Nagpal S, et al. Recurrently mutated genes differ between leptomeningeal and solid lung cancer brain metastases. J Thorac Oncol. 2018;13(7):1022–7.

Article  Google Scholar 

41.

Li L, Liu Z, Han R, Li L, Wang M, Huang D, et al. Genetic heterogeneity between paired primary and brain metastases in lung adenocarcinoma. Clin Med Insights Oncol. 2020;14:1179554920947335.

Article  Google Scholar 

42.

Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017;376(22):2109–21.

CAS  Article  Google Scholar 

留言 (0)

沒有登入
gif